JP Morgan has recently reduced Editas Medicine Inc (EDIT) stock to Underweight rating, as announced on December 16, 2024, according to Finviz. Earlier, on December 13, 2024, Truist had reduced the ...

BioMed Realty, one of the biggest labspace owners in the Boston area, recently acquired 215 First St., 150 Second St. and 11 ...

Cell Therapy Regenerative medicine Market. The Cell Therapy Regenerative Medicine market is poised for significant growth, driven by advancements in techno ...

At NYU Grossman School of Medicine, our commitment to innovation has led us to bold new ways of bridging the gap between basic science research, medical education, and quality of patient care. With ...